Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Influenza vaccine, inactivated, surface antigen is a subunit influenza vaccine composed of purified viral surface glycoproteins, specifically hemagglutinin (HA) and neuraminidase (NA). Unlike whole-virus or split-virion vaccines, the surface antigen formulation undergoes additional purification steps to remove internal viral proteins and lipids, which is intended to minimize systemic reactogenicity while maintaining immunogenicity. The vaccine functions by stimulating the production of neutralizing antibodies against the HA protein, thereby blocking the virus's ability to bind to sialic acid receptors on host epithelial cells and preventing infection. The Complexo Hospitalario Universitario De Santiago has been involved in evaluating the effectiveness of this vaccine type in preventing secondary complications of influenza, such as pneumonia and the exacerbation of underlying cardiorespiratory diseases, particularly in elderly and high-risk populations through large-scale effectiveness studies like GaliFlu.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on influenza vaccine, inactivated, surface antigen.